MSFinals-2897

A 35-year-old man visits the renal clinic eight weeks after a successful renal transplant. He has some inquiries about his immunosuppression. The consultant explains that the typical regimen for renal transplant patients involves the use of an induction agent initially, followed by a combination of a calcineurin inhibitor, antimetabolite, and steroids. This combination is intended to prevent rejection of the transplanted kidney. Can you identify the agent that acts as a purine analogue to disrupt DNA synthesis and induce apoptosis in rapidly dividing cells?